Analyses of dynamic beat-to-beat QT-TQ interval (ECG restitution) changes in humans under normal sinus rhythm and prior to an event of torsades de pointes during QT prolongation caused by sotalol

Ann Noninvasive Electrocardiol. 2007 Oct;12(4):338-48. doi: 10.1111/j.1542-474X.2007.00183.x.

Abstract

Background: Restitution through intracardiac pacing has been used to assess arrhythmia vulnerability. We examined whether analyses of sequential beat-to-beat QT and TQ interval measures can be used to quantify ECG restitution changes under normal sinus rhythm.

Methods: The QT, R-R and TQ intervals were examined 22.5 hour Holter monitoring before and after oral sotalol in normal male and female volunteers. Additionally, comparisons were made to those observed in the time-matched dataset prior to torsades de pointes in a heart diseased patient that received a single dose of sotalol.

Results: Sotalol increased QT, R-R and TQ intervals 71, 101, and 125 ms after 160 mg (n = 38) and 194, 235, and 135 ms after 320 mg (n = 19) during maximum plasma concentrations, respectively. The percentage of beats with a QT/TQ ratio >1 was reduced 25% over the entire 22.5 hours after sotalol and the lower TQ interval boundary (5th quantile) was increased 22-30%. In contrast, 99% of the beats prior to torsades de pointes had a QT/TQ ratio > 1 and the median TQ interval was below the lower 98% confidence bounds of normals before and after sotalol.

Conclusions: ECG restitution changes are quantifiable under varying states (nocturnally, beta-adrenergic blockade, QT prolongation) in healthy subjects.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Anti-Arrhythmia Agents / pharmacology*
  • Electrocardiography, Ambulatory*
  • Female
  • Humans
  • Long QT Syndrome / chemically induced*
  • Long QT Syndrome / physiopathology*
  • Male
  • Middle Aged
  • Sotalol / pharmacology*
  • Statistics, Nonparametric
  • Torsades de Pointes / chemically induced*
  • Torsades de Pointes / physiopathology*

Substances

  • Anti-Arrhythmia Agents
  • Sotalol